AGM Presentation
Released
Released
Announcement PDF
0
AGM
Presentation
ASX:RCE | FSE:R9Q
6 November 2026
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does
not purport to contain all the information that a prospective investor may require in connection
with any
potential investment in the Company. You should not treat the contents of this presentation,
or any information provided in connection with it, as financial advice, financial product advice
or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any
of its officers, advisers, agents or employees as to the accuracy, completeness or
reasonableness of the information, statements, opinions or matters (express or implied)
arising out of, contained in or derived from this presentation or provided in connection with it,
or any omission from this presentation, nor as to the attainability of any estimates, forecasts
or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own
independent inquiries into the matters contained in the presentation and make your own
independent decisions about the affairs, financial position or prospects of the Company. The
Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and
employees accept any responsibility or liability to you or to any other person or entity arising
out of this presentation including pursuant to the general law (whether for negligence, under
statute or otherwise), or under the Australian Securities and Investments Commission Act
2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding
provision of any Australian state or territory legislation (or the law of any similar legislation in
any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities. It does not include all available information and should not be
used in isolation as a basis to invest in the Company.
1
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of
the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are
based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of
factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any
intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not place
undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not
warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1933 (“Securities Act”). The Company’s shares have not been, and will not be,
registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States,
and may not be offered or sold in the United States or to any US person without being so registered or
pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Company
Overview
Recce Pharmaceuticals – Company Overview
RECCE® 327 has received Qualified Infectious Disease Product (QIDP)
Designation from the U.S. Food and Drug Administration. If approved in
the US, QDIP provides an additional 5 years of market exclusivity, and the
product is eligible for fast-track designation and priority review.
RECCE® 327 added to World Health Organization’s List
of Antibacterial Products in Clinical Development.
3
Recce Pharmaceuticals is an Australian clinical stage anti-infective company
Products address the global healthcare crisis of antibiotic resistance: working faster than
traditional antibiotics and against multidrug resistant bacteria
- Patient dosing well underway for Phase 3 clinical trials in Indonesia and Australia of lead asset
RECCE® 327 Gel for the treatment of Diabetic Foot Infections
- A 75-patient dataset from the Indonesian Phase 3 trial has been submitted to an independent Data
Monitoring Committee (DMC), expected to meet as soon as mid-November 2026.
- Signed an exclusive licensing and commercialisation agreement with Arrotex
Pharmaceuticals for R327G in AU and NZ.
- Non-binding term sheet signed with a leading Middle Eastern pharmaceutical
company for a proposed 10-year exclusive, multi-country licensing agreement.
Multiple clinical indications and formulations addressing unmet medical needs
Agreements with US Defense Burn Research Program and US Army Medical Research Institute
of Infectious Diseases further support Recce's product potential
Board and Management Structure
4
Dr John Prendergast – Chairman
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
US-based, current Chairman and Co-founder of Palatin Technologies, Inc.
(NYSE: PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With
extensive experience in the international commercialisation of pharmaceutical
technologies, Dr Prendergast has been responsible for the approval of three
new drug applications and played a pivotal role in the successful sale of
Vylessi® to Cosette Pharmaceuticals.
James Graham – Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings
extensive experience in marketing, business development, and the
commercialisation of early-stage technologies with global potential. With a
proven track record of growing globally focused companies, Mr Graham has
applied his expertise to Recce, including serving on its Board of Directors. He
has participated in nearly every capital raise to date, demonstrating a strong
commitment to expanding Recce’s commercial opportunities and clinical
programs.
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
US based, Director of Palatin Technologies. Over three decades of senior
pharmaceutical experience incl. President and MD of Janssen Research
Foundation (Johnson & Johnson). Dr Dunton has advanced a number of
blockbuster antibiotics through regulatory review and commercialisation at
Fortune 500 companies including Roche. Dr Dunton has been responsible for
the approval of approximately 20 New Drug Applications. Dr. Dunton played
a key role in the sale of Vylessi® to Cosette Pharmaceuticals.
Michele Dilizia – Executive Director & Chief Scientific Officer
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
Co-inventor and qualified medical scientist with a specialisation in medical
microbiology and regulatory affairs. Ms Dilizia successfully co-led the
research and development of Recce’s suite of anti- infective
compounds, resulting in a portfolio of granted patents across the globe,
including a Qualified Infectious Disease Product designation with the U.S.
FDA.
Dr Justin Ward – Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem
A quality control expert who has worked with leading pharmaceutical
companies. He previously held a technical role with Pfizer, involving providing
data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing
Recce’s research and development and manufacturing up to US FDA
requirements.
Alistair McKeough – Non-Executive Director
As announced to the ASX on 4 November 2026, Mr Alistair McKeough retires at the
conclusion of the 2026 AGM.
Mr McKeough is an experienced executive and solicitor. Before being
appointed as a non-executive director in 2022, Alistair served as Recce’s
company secretary and he has been involved with the company since 2017.
Alistair has extensive experience in a variety of private and listed corporations
across many sectors, including professional services, technology, financial
services, charities, health, biotech, childcare and education. Recent roles
include Managing Director of a legal practice specialising in equity capital
markets and advice to listed companies and as part of the senior leadership
team at share registry, Automic Group.
recce.com.au
Capital Structure and Share Price
Capital Structure – November 2026
ASX & FSE Code RCE, R9Q
Share Price AUD $0.330
3-Month Average
Daily Volume
254.54k
Shares on Issue 305.84 million
Unlisted Options 15.4 million
Market Capitalisation AUD $102.46 million
Top 20 Shareholders 54%
RCE Share Price and Volume Chart – 12 Months (price shown in AUD)
Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives
Volume Close $
5
• Estimated R&D rebate of A$7.5 million from the ATO in 2026. Refer to the Appendix 4C lodged on 30 October 2026 for the Company’s
current cash position.
Expected Non-Dilutive Funding
$-
$0.10
$0.20
$0.30
$0.40
$0.50
$0.60
$0.70
$0.80
-
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
recce.com.au
Company Pipeline driven by 1st approval in Diabetic Foot Infections
2026 2027
R327G Topical
Diabetic foot infection gel
Indonesia / ASEAN Independent DMC review
75-patient unblinded dataset
Potential
accelerated
registration
Registrational Phase 3 trial recruitment
and dosing continue uninterrupted
155-patient
interim analysis
and readout
R327G
registrable
in Indonesia
R327G Topical
DFI / ABSSSI — Australia / USA Australia Phase 3 clinical trial designed to support TGA and FDA applications
R327 I.V. Program Phase I complete, safe and well tolerated
Phase II trials of R327 I.V.
R327 Inhaled — Lung Infections
Hospital & ventilator acquired pneumonia
Preclinical trials of R327 Nebuliser
Civil & U.S. Department of War
Programs
Burn wound infections — USA
Preclinical trials of R327G with the U.S. Department of War
Mechanism of Action (MoA)
MoA paper
published
Planned activity
Conditional on DMC recommendation
*The DMC may recommend progressing toward regulatory submission, continuing the trial unchanged, amending the protocol, or pausing the trial. Refer to RCE ASX announcement, 20 October 2026.
The information and forecasts presented reflect management's current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate funding, and are subject to
known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections and strategic priorities as circumstances change.
6
Phase I/II trials of R327 Inhaled
Phase I/II trials of R327 for Burn Wound Infections
Pipeline Programs
Core Programs R327G
registrable
in ASEAN
If supportive: early
regulatory
submission*
Commercial
& Licensing
7
recce.com.au
R327G Key Addressable DFI Markets
Key market
Estimated patients with
mild or moderate DFI per
year
Potential Total
Addressable Market
Commercial partner
Australia & NZ
1.79m diabetic adults1
Indonesia
20.4m diabetic adults1
Middle East/North Africa
84.7m diabetic adults1
Combined
34,400 Approx. A$73m
391,700 Approx. A$834m
1,626,200 Approx. A$3.46b
2,052,300 Approx. A$4.37b
Binding exclusive licence
Memorandum of Understanding
Non-binding term sheet
signed with Leading MENA
pharmaceutical company
1 International Diabetes Federation
2 Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. J Clin Orthop Trauma. 2021.
3 Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023
4 US$1,500 (A$2,130) per treatment is the proposed selling price in a non-binding term sheet for the MENA region, subject to agreement with the KSA regulatory authority (see ASX announcement,
“Recce Signs Middle East Licensing Term Sheet”, dated 27 May 2026). The same price is applied to all markets for illustration only. Prices in Australia, New Zealand and Indonesia have not been
set and may differ materially. Figures assume every patient with mild or moderate DFI is treated with R327G. They are not forecasts of Recce sales, revenue or market share. Pricing, reimbursement
and uptake in each market are unknown. R327G is investigational and is not approved in any market..
5 Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA. Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system. Clin Infect Dis. 2007
Assumptions across all markets: 4% DFU incidence per annum in Diabetic Adults2 x 60% of diabetic foot ulcers become infected3 x 80% Patients with
Mild/Moderate DFI5 x A$2,130 per treatment (US$1,500)4
Australia and New Zealand Licence Agreement
9
Recce has signed a binding exclusive licence agreement with Arrotex Pharmaceuticals to commercialise R327G
Partnership with Arrotex Pharmaceuticals
• One of Australia's largest and most diversified
pharmaceutical companies
• Exclusive ANZ rights for R327G in diabetic foot
infection and ABSSSI
A direct commercial route for R327G in Australia and New Zealand
Agreement Highlights
Commercial Costs Covered
• Significant profit share of gross margin, paid quarterly
• Arrotex funds all commercialisation — regulatory filings,
PBS and Pharmac submissions, sales and marketing
Recce Retains IP and Supply
• Exclusive manufacturer and supplier of R327G to
Arrotex
• Retains all intellectual property and all rights outside the
territory
AUS/NZ DFI Market
• 50,000 Australians living with a diabetes-related foot
ulcer, with 300,000 more at risk1
Source: ASX announcement “License and Commercialisation Agreement in AUS/NZ for R327G”, 22 October 2026 for a summary of the key terms of the agreement.
1 Chan TL, Sadler S, Searle A, Hennessy K, Lanting S, Chuter V. Social Determinants of Diabetes-Related Foot Ulcer Healing and Amputation in Australia: A Systematic Review. J Foot Ankle Res.
2026
Unlocks
MENA Diabetes Market
• The MENA region has a diabetes prevalence of 17.6% with over 84 million people living with diabetes – in Saudi Arabia,
23.1% of the adult population have been diagnosed with diabetes
• The non-binding Term Sheet coverage is across the KSA, GCC countries (UAE, Kuwait, Oman, Bahrain, Qatar), Iraq,
Egypt, Algeria and Morocco
Proposed Pricing
• Non-binding Term Sheet stipulates a proposed selling price of US$1,500 per treatment or a price mutually agreed with
the KSA regulatory authority
• Recce expected to receive 30% of the Net Selling Price with an additional 6% annual royalty on net sales >USD$50
million/year
Data Harmonisation
from Indonesia
• Successful data read outs in Indonesia together with subsequent regulatory approval would support commercialisation in
Indonesia and may support similar regulatory approval and commercialisation in other ASEAN markets.
• Pending positive Phase 3 clinical trial results from the ongoing Indonesian trial, no additional clinical trials are expected to
be required to support a marketing authorisation application in Saudi Arabia
Commercial Partnership
with Leading Company
• The partner is recognised as one of the leading pharmaceutical companies in the MENA region
• With a strong sales portfolio of products across dermatology, endocrinology and infectious diseases and established
market access throughout the region, the partner is well positioned to accelerate the adoption and distribution of R327G
Middle Eastern Pharmaceutical Company Term Sheet
10
Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive
multi-country licensing agreement for the licensing of R327G through the MENA region
Non-binding term sheet is a positive step towards the potential commercialisation of R327G across one of the world's
most significant diabetes markets
Term Sheet Highlights
Selected ASX Companies with active Phase 3 Programs
Eight ASX companies are advancing Phase 3 therapeutic trials — four have failed since 2025
Active Phase 3 Programs – ASX Companies Market Cap (A$)
Phase 3 Failures Since 2025
Telix Pharmaceuticals (ASX: TLX)
Prostate cancer therapy
4.53B
Mesoblast (ASX: MSB)
Chronic low back pain; Duchenne
2.73B
Neuren Pharmaceuticals (ASX: NEU)
Phelan-McDermid syndrome
2.51B
Clarity Pharmaceuticals (ASX: CU6)
Prostate cancer imaging
514.85M
Clinuvel Pharmaceuticals (ASX: CUV)
Vitiligo
357.45M
Dimerix (ASX: DXB)
FSGS kidney disease
120.08M
Recce Pharmaceuticals (ASX: RCE)
Diabetic foot infection (Indonesia & Australia)
102.46M
Paradigm Biopharmaceuticals (ASX: PAR)
Sep 2026
Results below continuation threshold
Cynata Therapeutics (ASX: CYP)
Jun 2026
Missed both co-primary endpoints
Immutep (ASX: IMM)
Mar 2026
Phase 3 discontinued
Opthea (ASX: OPT)
Mar 2025
Phase 3 discontinued
Recce also has earlier-stage programs in IV, Inhalation,
Burn Wounds
Market data as of 5 November 2026. 11
Recce is the only ASX-listed company with an
anti-infective in Phase 3 clinical trials5
Racura Oncology (ASX: RAC)
AML
274.50M
1 ASX announcement “Phase 3 Interim Result Below Continuation Threshold”, Paradigm Biopharmaceuticals (ASX: PAR), 23 September 2026.
2 ASX announcement “CYP-004 Osteoarthritis Trial Results”, Cynata Therapeutics (ASX: CYP), 19 June 2026.
3 ASX announcement “TACTI-004 to be discontinued following futility analysis”, Immutep (ASX: IMM), 13 March 2026.
4 ASX announcement “Opthea Announces Decision to Discontinue Wet AMD Trials”, Opthea (ASX: OPT), 31 March 2025.
5 To the Company's knowledge, as at 6 November 2026.
RECCE® 327
Topical Gel
12
Dual Phase 3 Clinical Trial Strategy
13
Two Phase 3 Clinical Trials, in Australia and Indonesia
Registrational, multi-centre, double-blind, placebo-controlled
• Primary Endpoint: Assess the clinical response of the DFI
according to the Lipsky Scale. Secondary Endpoints: DFI total
wound score and safety of R327G
• 310 patients randomised to R327G or placebo, with a pre-
specified interim analysis at 155 patients
2026 Milestones:
90 Patients Enrolled1
BPOM routine regulatory inspection of the Indonesian trial site
completed with no findings preventing the study from continuing
A 75-patient dataset has been submitted to the independent
DMC for unblinded review. A prior review of blinded,
pooled data by clinical experts and a statistician indicates
strong efficacy along with a very positive safety profile. 1
Australia Phase 3
Indonesia Phase 3
Conducted to TGA and US FDA regulatory standards, Active-
comparator design: R327G versus one of four physician-
selected comparator antibiotics
• Primary Endpoint: Assess the clinical response of the DFI
according to the Lipsky Scale. Secondary Endpoints: DFI total
wound score and safety of R327G
• 208 participants, with interim analysis after 104 participants
2026 Milestones:
HREC approval received to advance the trial to a pivotal Phase 3,
with a protocol amendment expanding eligibility to include mild
and moderate DFI — together ~80% of DFI presentations
Further HREC approval for head-to-head comparison against
existing antibiotics used for treating DFIs , with interim analysis
after 104 participants
Over 20.4 million adults in Indonesia are living with diabetes
— more than 1 in every 10 adults
Diabetes is responsible for 60% of all non-traumatic lower-limb
amputations in Australia, which has one of the worst diabetes-
related amputation rates in the developed world
1.Refer to RCE ASX Announcement 20 October 2026.
Indonesia Phase 3: Independent DMC Review Underway
14
Blinded Data across 75 patients has shown
*Refer to RCE ASX Announcement 20 October 2026
Milestones ahead A data set of 75 patients has been formally submitted to the
independent Data Monitoring Committee who will unblind the
data. This review is separate from the previously communicated
interim analysis milestone of 155 patients. The Phase 3 study
remains ongoing, with subsequent clinical and regulatory
milestones subject to study outcomes, DMC recommendations
and regulatory requirements.
75 90
Patients currently enrolled
- recruiting at 4.5 patients/week
• Review of the blinded data indicates strong efficacy
across the study population
• RECCE® 327 Gel (R327G) continues to demonstrate
an excellent safety and tolerability profile
• Independent DMC Review Readout*
• 155 Patient Interim Analysis
• Potential regulatory submission, subject to DMC
recommendation, trial results and BPOM review
Patients submitted for
data review*
Phase 3 DFI Clinical Trial in Australia
15
Milestones
Achieved
• 208 patients total with interim analysis to be conducted after 104 participants
• Patient dosing continues under existing protocol
• Wound imaging added, calibrated digital photography for standardised, objective assessment
Participants
Head-to-head comparison against existing antibiotics used for treating DFIs – has the
potential to become the first standard of care used by physicians for the treatment of DFIs
HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component
Protocol amendment adds moderate DFI. Mild and Moderate DFI together represent 80% of
DFI presentations.
If successful, R327G positioned as first standard of care treatment for DFIs
Expansion of Phase 3 global regulatory strategy targeting approvals across Australia (TGA),
the US (FDA), MENA and ASEAN
Progress with the U.S. Department of War
16
Collaboration with the U.S. Department of War in advancing next-generation of anti-infectives
Testing R327 for the Acute Treatment
of Burn Wounds and Downstream
Sequelae
CDMRP Grant
Testing R327 against a panel of
biothreat pathogens
1st CRADA
U.S. Army Medical
Research Institute of
Infectious Diseases
(USAMRIID)
To evaluate the efficacy of R327G in
reducing the bioburden of Pseudomonas
aeruginosa / Staphylococcus aureus in
Burn Wounds
2nd CRADA – Feb 2026
Antimicrobial resistance ranked the second-
highest funding priority in the plan, with
US$4.46 billion earmarked for broad-
spectrum antimicrobials — directly aligned
with Recce's technology.2
The United States Government released a five-year, US$66.9 billion medical
countermeasures funding strategy to strengthen national defences against
pandemics and drug-resistant superbugs.
Congressionally Directed Medical
Research Programs (CDMRP)
Cooperative Research and
Development Agreement (CRADA)1
U.S. Army Institute of Surgical
Research (USAISR)
US$2 million
1 CRADAs are collaborative research agreements and do not involve direct funding to Recce.
2 Recce has not applied for or been awarded funding under this strategy.
Robust Worldwide Intellectual Property Portfolio
17
Family 1 group relates to the Company’s Unique
and Highly Economical Manufacturing Process and
use of the Polymer in Treatment of Diseases.
Family 2 relates to the Method of Manufacture,
Administration and Application to Treat a Broad
Range of Common Human Infections.
Family 3 relates to a Method of Treatment of a
Broad Range of Viral Infections, particularly
Parenteral Viral Infection.
Family 4 relates to Process for Preparation of
Biologically Active Copolymer, other Patent
Cooperation Treaty countries pending/granted.
Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets.
Filed
Patent
Family 1
Expiry
Patent
Family 2
Expiry
Patent
Family 3
Expiry
Patent
Family 4
Expiry
Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
USA ✓ 2029 ✓ 2037 ✓ 2037 Pending
Europe ✓ 2028 ✓ 2037 ✓ 2037 Pending
Germany ✓ 2028 ✓ 2037 ✓ 2037
Spain ✓ 2028 ✓ 2037 ✓ 2037
France ✓ 2029 ✓ 2037 ✓ 2037
UK ✓ 2028 ✓ 2037 ✓ 2037
Italy ✓ 2028 ✓ 2037 ✓ 2037
Sweden ✓ 2028 ✓ 2037 ✓ 2037
Japan ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
China ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
HK Pending 2028 Pending 2037 ✓ 2037 ✓ 2041
Israel ✓ 2041
Canada ✓ 2041
Brazil ✓ 2041
Vietnam ✓ 2041
recce.com.au
Thank you
Share your feedback
Discover